NZ501990A - Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody - Google Patents

Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody

Info

Publication number
NZ501990A
NZ501990A NZ501990A NZ50199098A NZ501990A NZ 501990 A NZ501990 A NZ 501990A NZ 501990 A NZ501990 A NZ 501990A NZ 50199098 A NZ50199098 A NZ 50199098A NZ 501990 A NZ501990 A NZ 501990A
Authority
NZ
New Zealand
Prior art keywords
antigen
recognise
recombinant
antibody
compositions containing
Prior art date
Application number
NZ501990A
Inventor
Michael D Dan
Original Assignee
Viventia Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viventia Biotech Inc filed Critical Viventia Biotech Inc
Publication of NZ501990A publication Critical patent/NZ501990A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A composition of an isolated polynucleotide sequence that encodes an antigen- binding fragment of antibodies specific for GD2, used in the treatment of tumours.
NZ501990A 1997-07-08 1998-07-08 Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody NZ501990A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5194597P 1997-07-08 1997-07-08
PCT/IB1998/001046 WO1999002545A2 (en) 1997-07-08 1998-07-08 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Publications (1)

Publication Number Publication Date
NZ501990A true NZ501990A (en) 2002-09-27

Family

ID=21974384

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ501990A NZ501990A (en) 1997-07-08 1998-07-08 Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody

Country Status (6)

Country Link
EP (1) EP1000082A2 (en)
JP (1) JP2001509369A (en)
AU (1) AU7927398A (en)
CA (1) CA2295375A1 (en)
NZ (1) NZ501990A (en)
WO (1) WO1999002545A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2249762T3 (en) 1994-03-08 2006-04-01 Human Genome Sciences, Inc. GROWTH FACTOR OF THE VASCULAR ENDOTELIUM 2.
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP1265918A1 (en) * 2000-03-15 2002-12-18 Incyte Genomics, Inc. Human immune response proteins
NZ518077A (en) 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
DE10059930A1 (en) * 2000-11-23 2002-05-29 Fischer Peter Composition for treating tumors that produce disialoganglioside GD2, comprises human antibody fragment able to induce anti-idiotypic antibodies
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
EP2228389B1 (en) 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US7473424B2 (en) * 2003-01-31 2009-01-06 The Scripps Research Institute Anti-dengue virus antibodies and compositions
TWI434855B (en) * 2006-11-21 2014-04-21 Hoffmann La Roche Conjugate and its use as a standard in an immunoassay
CN105916882A (en) * 2013-12-16 2016-08-31 得克萨斯技术大学联合体 Anti-RON monoclonal antibodies as a cytotoxic drug delivery system for targeted cancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
CA2209172C (en) * 1994-12-28 2007-04-10 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma

Also Published As

Publication number Publication date
CA2295375A1 (en) 1999-01-21
JP2001509369A (en) 2001-07-24
EP1000082A2 (en) 2000-05-17
WO1999002545A3 (en) 1999-04-01
WO1999002545A2 (en) 1999-01-21
AU7927398A (en) 1999-02-08

Similar Documents

Publication Publication Date Title
NZ501990A (en) Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
AU3117201A (en) Methods and compositions for generating human monoclonal antibodies
ES8405071A1 (en) Covalent conjugates of an enzyme and an antibody, and medicinal compositions containing these conjugates.
HK1076128A1 (en) Humanized collagen antibodies and related methods
MX9700553A (en) Antibodies which activate an erythropoietin receptor.
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
AU3327701A (en) Humanized anti-ccr2 antibodies and methods of use therefor
UA89017C2 (en) HUMAN ANTIBODY THAT SPECIFICALLY BINDS TO hTNFSF13B
GEP20104997B (en) Composition comprising anther2 antibodies
AR085874A2 (en) A MONOCLONAL ANTIBODY OR A FRAGMENT OF THE SAME THAT JOINS AN ANTIGEN
MY145191A (en) Human antibodies that bind human il-12 and methods for producing
NO942850D0 (en)
BR9809778A (en) Isolated polynucleotide, expression vector, isolated peptide or polypeptide, antibody, process for producing the same, antibody fragments, single chain antibodies or humanized antibodies, and anti-idiotypic antibody.
AU676859B2 (en) Synthetic peptides, antibodies against them and their use
CA2068222A1 (en) Monoclonal antibodies
MY105946A (en) Antagonists of gm-csf derived from the carboxyl terminus.
EP2088158A3 (en) Monoclonal antibody against the CCR5 chemokine receptor
EP1411962A4 (en) Monoclonal antibody therapy for pancreas cancer
IL187595A (en) Pharmaceutical composition comprising a monoclonal antitumor antibody and its manufacture
SI1396501T1 (en) Antibodies for identifying and/or isolating at least one cell population which is selected from the group comprising haematopoietic stem cells, neuronal stem cells, neuronal precursor cells, mesenchymal stem cells and mesenchymal precursor cells
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: VIVENTIA BIOTECH INC, CA

Free format text: OLD OWNER(S): NOVOPHARM BIOTECH INCORPORATED

PSEA Patent sealed
RENW Renewal (renewal fees accepted)